TherapeuticsMD, Inc. (TXMD) P/E Ratio History
Deep ValueTrading at -39.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2007–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, TherapeuticsMD, Inc. (TXMD) trades at a price-to-earnings ratio of -39.6x, with a stock price of $1.95 and trailing twelve-month earnings per share of $0.02.
The current P/E is 246% below its 5-year average of 27.2x. Over the past five years, TXMD's P/E has ranged from a low of 0.7x to a high of 131.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, TXMD trades at a 279% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, TXMD trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TXMD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TXMD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
TXMD P/E vs Peers
Therapy-focused branded biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 40.1 | 5.99Best | +14% | |
| $2B | 23.9 | - | +419%Best | |
| $383B | 91.4 | - | -1% | |
| $143B | 18.5Lowest | - | -4% | |
| $37B | 26.2 | - | +183% | |
| $90B | 19.6 | - | +49% | |
| $52B | 34.4 | - | +87% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
TXMD Historical P/E Data (2007–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $2.02 | $0.02 | 131.2x | +382% |
| FY2025 Q3 | - | $1.08 | $0.03 | 41.4x | +52% |
| FY2023 Q1 | Mar 31 2023 | $3.75 | $5.34 | 0.7x | -97% |
| FY2008 Q1 | Mar 31 2008 | $850.00 | $371.82 | 2.3x | -92% |
| FY2007 Q4 | Dec 31 2007 | $1683.33 | $493.91 | 3.4x | -87% |
| FY2007 Q3 | Sep 30 2007 | $2750.00 | $501.55 | 5.5x | -80% |
| FY2007 Q2 | Jun 30 2007 | $4166.67 | $687.06 | 6.1x | -78% |
Average P/E for displayed period: 27.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
19+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TXMD — Frequently Asked Questions
Quick answers to the most common questions about buying TXMD stock.
What is TXMD's P/E ratio?
TherapeuticsMD, Inc. (TXMD) trailing twelve-month P/E ratio is -39.6x, based on TTM diluted EPS of $0.02. The 5-year average P/E is 27.2x and the historical range spans 0.7x to 131.2x.
Is TXMD stock overvalued or undervalued?
TXMD trades at -39.6x P/E, below its 5-year average of 27.2x. At the 0th percentile of its historical range (0.7x–131.2x), the stock is priced at a discount to its own history.
Is TXMD stock expensive?
No, TXMD is not expensive on a historical basis. The current P/E of -39.6x is below the 5-year average of 27.2x and sits at the 0th percentile of its valuation range.
What is TXMD's historical P/E range?
Over the past 5 years, TXMD's P/E ratio has ranged from 0.7x to 131.2x, with a median of 5.5x and an average of 27.2x. The current P/E of -39.6x places the stock at the 0th percentile of this range. Full historical data spans 2007–2026.
How does TXMD's P/E compare to the S&P 500?
TXMD trades at -39.6x P/E versus the S&P 500 median of 24.4x. The 262% discount to the market suggests lower growth expectations or perceived higher risk.
How does TXMD's valuation compare to Healthcare peers?
TherapeuticsMD, Inc. P/E of -39.6x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is TXMD's PEG ratio?
TXMD PEG ratio is N/A, based on a P/E of -39.6x and EPS growth of 74.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is TXMD's earnings yield?
TXMD earnings yield is N/A, the inverse of its -39.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.